WHO COOPERATIVE TRIAL ON PRIMARY PREVENTION OF ISCHAEMIC HEART DISEASE WITH CLOFIBRATE TO LOWER SERUM CHOLESTEROL: FINAL MORTALITY FOLLOW-UP Report of the Committee of Principal Investigators

@article{1984WHOCT,
  title={WHO COOPERATIVE TRIAL ON PRIMARY PREVENTION OF ISCHAEMIC HEART DISEASE WITH CLOFIBRATE TO LOWER SERUM CHOLESTEROL: FINAL MORTALITY FOLLOW-UP Report of the Committee of Principal Investigators},
  author={},
  journal={The Lancet},
  year={1984},
  volume={324},
  pages={600-604}
}
  • Published 15 September 1984
  • Medicine
  • The Lancet
Measurement and Management of Hyperlipidemia for the Primary Prevention of Coronary Heart Disease
TLDR
Five major randomized drug intervention trials for primary prevention of coronary heart disease showed that cholestyramine, gemfibrozil, clofibrate, and pravastatin can reduce the rate of nonfatal myocardial infarctions in middle-aged men.
Cholesterol trials and mortality.
TLDR
The importance of all-cause mortality data is illustrated by comparing survival in three different sets of the larger controlled lipid trials that underpin meta-analyses by considering that the presentation of key mortality/survival data adds to existing meta-Analyses to aid personal treatment decisions.
Fibrates: no ACCORD on their use in the treatment of dyslipidaemia
TLDR
Fenofibrate and bezafibrate are reasonable second-line therapies for dyslipidaemia and in diabetes but add little endpoint benefit except possibly in patients with a significant degree of atherogenic dyslipidemia (high triglycerides and low HDL-cholesterol).
Treatment of patients with mild hypertension.
TLDR
The ethical justifications for the use of drugs to treat mild hypertension have not been completely fulfilled and the degree of risk for most persons with mild hypertension is relatively small and that those who are at higher risk can be identified reasonably well.
Use of fibrates in the metabolic syndrome: A review.
TLDR
This review considers patient subgroups such as those with the metabolic syndrome and those needing treatment to prevent the microvascular complications associated with diabetes in whom fibrates may be useful, and presents other features of fibrate treatment the authors have observed in clinical practice.
Cholesterol reduction yields clinical benefit: impact of statin trials.
TLDR
Adding the results from the statin trials confirmed the original conclusion that lowering cholesterol is clinically beneficial and the relationships (slope) between cholesterol lowering and reduction in CHD and total mortality risk became stronger, and the standard error of the estimated slopes decreased by about half.
Cholesterol lowering and the reduction of CHD incidence and total mortality: Results from a meta-analysis of randomized trials
  • I. Holme
  • Medicine
    Cardiovascular Drugs and Therapy
  • 2004
TLDR
This editorial reports on a meta-analysis done on cholesterol-lowering trials that found cholesterol reduction had to be at least 8–9% to outweigh the negative impact of treatment on total mortality.
Cholesterol, Atherosclerosis and Coronary Disease in the UK, 1950–2000, vol. 27.
TLDR
The role of diet in heart disease had always been controversial in the UK, although extreme diets could reduce cholesterol, patient conformity remains difficult and recommended limits on the composition of dietary fat were agreed.
The Origins and Early Evolution of Epidemiologic Research in Cardiovascular Diseases: A Tabular Record of Cohort and Case-Control Studies and Preventive Trials Initiated From 1946 to 1976.
This article serves as a ready reference guide to the pioneering formal studies in cardiovascular disease (CVD) epidemiology initiated during 3 decades of the subject's evolution into an established
Endocrinology and Dialysis: Management of Lipid Abnormalities Associated with End‐Stage Renal Disease
TLDR
The pharmacokinetics of lipid lowering drugs are altered in patients with ESRD and must be considered when treating this group of patients and the major classes of drugs used to treat dyslipidemia are reviewed.
...
...